Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
40 participants
INTERVENTIONAL
2024-03-11
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
Sites in the control condition will be asked to complete appropriate/relevant surveys and interviews with minor modifications as needed and use the same Electronic Health Record Data Abstraction process.
No interventions assigned to this group
Experimental Group
Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.
Engaged Approach to Lung Cancer Screening
Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.
Staff-facing materials include:
* Program website/manual/toolkit overview
* Implementation insights with experts video series
* Clinical placement placards
* Program and clinician communication tools
Candidate-facing materials include:
* Program welcome letter
* Maps and directions template
* Communication preferences
* Candidate letter templates (N=\~8)
* Program newsletter template and instructions
* Lung nodule size comparison chart
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Engaged Approach to Lung Cancer Screening
Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.
Staff-facing materials include:
* Program website/manual/toolkit overview
* Implementation insights with experts video series
* Clinical placement placards
* Program and clinician communication tools
Candidate-facing materials include:
* Program welcome letter
* Maps and directions template
* Communication preferences
* Candidate letter templates (N=\~8)
* Program newsletter template and instructions
* Lung nodule size comparison chart
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to identify a primary contact person for LCS program operations (e.g., program coordinator, program navigator, program manager, etc.)
* Identified staff member of the LCS program site
* \>18 years of age
* Must be able to complete study surveys and interviews in English
* Willing to provide informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jamie Studts, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Denver
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Hospital
Denver, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-3063.cc
Identifier Type: -
Identifier Source: org_study_id